Patents by Inventor Rajiv Panwar
Rajiv Panwar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958908Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 24, 2020Date of Patent: April 16, 2024Assignee: CRISPR THERAPEUTICS AGInventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20230135930Abstract: Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can be used for cancer therapy. They can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.Type: ApplicationFiled: April 24, 2020Publication date: May 4, 2023Applicant: Heidelberg Pharma Research GmbHInventors: Charlotte Fenton McDonagh, Rajiv Panwar, Torsten Hechler, Michael Kulke, Ganapathy N. Sarma, Andreas Pahl, Christoph Mueller, Wermer Simon, Christian Lutz, Francesca Gallo
-
Patent number: 11572411Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: November 17, 2020Date of Patent: February 7, 2023Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20220267441Abstract: Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.Type: ApplicationFiled: October 22, 2021Publication date: August 25, 2022Inventors: Anthony Boitano, Michael Cooke, Charlotte Fenton McDonagh, Rahul Palchaudhuri, Rajiv Panwar, Bradley Pearse, Paul Fredrick Widboom, Patricia Ann Cruite
-
Publication number: 20220226493Abstract: Antibody-drug conjugates (ADCs) comprising an anthracycline and an anti-CD117 antibody are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 21, 2021Publication date: July 21, 2022Inventors: Charlotte Fenton McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Publication number: 20220175944Abstract: Anti-CD117 antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 21, 2021Publication date: June 9, 2022Inventors: Charlotte F. McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Publication number: 20220177577Abstract: Anti-CD117 antibody-drug conjugates (ADCs) comprising calicheamicin and are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, are provided.Type: ApplicationFiled: October 22, 2021Publication date: June 9, 2022Inventors: Charlotte Fenton McDonagh, Anthony Boitano, Michael Cooke, Ganapathy N. Sarma, Rajiv Panwar
-
Patent number: 11318452Abstract: Hydrocarbon composition plays vital role in fuel quality. For gasoline/motor spirit applications the hydrocarbon should have more octane-possessing molecules from the groups of aromatics, naphthenics and isoparaffins, while n-paraffins are not preferred due to their poor octane. Among the high-octane groups, again aromatics occupy the top but not more than 35 vol % aromatics can be mixed in gasoline for engine applications to avoid harmful emission, But there is no single process that addresses so far the issue of co-producing all the desired hydrocarbon components in a single process. Thus, it is interesting to have a single once-through process working on single catalyst system to produce mixture of all three high-octane molecules namely, aromatics, naphthenics and isoparaffins directly from low-value, low-octane n-paraffin feed. Herein, we report a novel single-step catalytic process for the simultaneous production of aromatics, naphthenics and isoparaffins for gasoline and petrochemical applications.Type: GrantFiled: July 23, 2020Date of Patent: May 3, 2022Assignee: Council of Scientific & Industrial ResearchInventors: Nagabhatla Viswanadham, Anjan Ray, Sandeep Kumar Saxena, Rajiv Panwar
-
Publication number: 20210317228Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 17, 2020Publication date: October 14, 2021Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20210206872Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: November 24, 2020Publication date: July 8, 2021Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20210023537Abstract: Hydrocarbon composition plays vital role in fuel quality. For gasoline/motor spirit applications the hydrocarbon should have more octane-possessing molecules from the groups of aromatics, naphthenics and isoparaffins, while n-paraffins are not preferred due to their poor octane. Among the high-octane groups, again aromatics occupy the top but not more than 35 vol % aromatics can be mixed in gasoline for engine applications to avoid harmful emission, But there is no single process that addresses so far the issue of co-producing all the desired hydrocarbon components in a single process. Thus, it is interesting to have a single once-through process working on single catalyst system to produce mixture of all three high-octane molecules namely, aromatics, naphthenics and isoparaffins directly from low-value, low-octane n-paraffin feed. Herein, we report a novel single-step catalytic process for the simultaneous production of aromatics, naphthenics and isoparaffins for gasoline and petrochemical applications.Type: ApplicationFiled: July 23, 2020Publication date: January 28, 2021Inventors: Nagabhatla Viswanadham, Anjan Ray, Sandeep Kumar Saxena, Rajiv Panwar
-
Patent number: 10899843Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 26, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Patent number: 10882915Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: GrantFiled: October 23, 2018Date of Patent: January 5, 2021Assignee: Magenta Therapeutics, Inc.Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Publication number: 20200407440Abstract: Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.Type: ApplicationFiled: April 24, 2020Publication date: December 31, 2020Inventors: Charlotte Fenton McDonagh, Rajiv Panwar, Ganapathy N. Sarma, Torsten Hechler, Michael Kulke, Andreas Pahl, Christoph Mueller, Werner Simon, Christian Lutz, Francesca Gallo
-
Publication number: 20190153114Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, e.g., acute myeloid leukemia (AML) and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 23, 2018Publication date: May 23, 2019Inventors: Bradley R. Pearse, Michael Cooke, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jacob Glanville
-
Publication number: 20190144558Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.Type: ApplicationFiled: October 23, 2018Publication date: May 16, 2019Inventors: Bradley R. Pearse, Anthony Boitano, Rahul Palchaudhuri, Sean McDonough, Rajiv Panwar, Jonathan Philip Belk, Matthew Duncan Smith
-
Patent number: 9598649Abstract: The present invention discloses a single step catalytic process for the conversion of n-paraffins and naphtha to diesel range hydrocarbons. A bi-metallic Pt—Sn/ZSM-5 catalyst has been developed for the direct conversion of n-heptane as well as naphtha into diesel range hydrocarbons in a single step process.Type: GrantFiled: November 11, 2013Date of Patent: March 21, 2017Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Viswanadham Nagabhatla, Sreenivasulu Peta, Sandeep Kumar Saxena, Rajiv Panwar, Devaki Nandan, Jagdish Kumar
-
Publication number: 20150355187Abstract: The invention provides methods for delivery of payloads to targets in samples using mixed payload polymers. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provides methods for preparation of reagents for use in the methods of the invention.Type: ApplicationFiled: December 19, 2013Publication date: December 10, 2015Inventors: Joel Berniac, Rajiv Panwar
-
Publication number: 20150284643Abstract: The present invention discloses a single step catalytic process for the conversion of n-paraffins and naphtha to diesel range hydrocarbons. A bi-metallic Pt—Sn/ZSM-5 catalyst has been developed for the direct conversion of n-heptane as well as naphtha into diesel range hydrocarbons in a single step process.Type: ApplicationFiled: November 11, 2013Publication date: October 8, 2015Applicant: Council of Scientific and Industrial ResearchInventors: Viswanadham Nagabhatla, Sreenivasulu Peta, Sandeep Kumar Saxena, Rajiv Panwar, Devaki Nandan, Jagdish Kumar